|
|
Sangamo Therapeutics, Inc.
|
 |
||||||||
|
 |
  |
 |
|
|
||
 |
 |
 
|
return to message board, top of board |
Re: Rob Schott"What effect might this have on the company?" fortunately for all longs, SGMO has a redundant mgt structure Sr VP Schott "is responsible for leading Sangamo's clinical development organization across all phases of drug development and regulatory approval" whereas Sr VP Cockroft "oversees all clinical development activities and operations" you can't make this stuff up :-) |
||||||||||||
|
|
return to message board, top of board |
| Msg # | Subject | Author | Recs | Date Posted |
| 166929 | Re: Rob Schott | TECH32 | 0 | 8/9/2022 8:28:33 PM |
